Good things come in small packages: Therapeutic anti-tumor immunity induced by microRNA nanoparticles. Academic Article uri icon

Overview

abstract

  • Current ovarian cancer treatments based on surgery/chemotherapy show limited efficacy. Targeting immunosuppression is a requirement for the effectiveness of novel promising anti-tumor immunotherapies. Our latest work in preclinical models shows that nanoparticle-mediated delivery of immunostimulatory microRNAs specifically to tumor-associated leukocytes is sufficient to re-program immunological control of metastatic ovarian cancers.

publication date

  • September 1, 2012

Identity

PubMed Central ID

  • PMC3489762

Scopus Document Identifier

  • 79953154967

Digital Object Identifier (DOI)

  • 10.1126/science.1198443

PubMed ID

  • 23162774

Additional Document Info

volume

  • 1

issue

  • 6